Download Image
    
Share
  
Post
CK0802 for COVID-19
1 study with 30 patients
Hospital Icon Control
Hospital Icon CK0802 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 CK0802 studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -8% Mortality -8% RCTs -8% Late -8% FavorsCK0802 Favorscontrol
Jun 30
2023
 Gladstone et al., Blood Advances, doi:10.1182/bloodadvances.2022009619 Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS
8% higher mortality (p=0.91) and 27% higher combined mortality/intubation (p=0.42). RCT 45 critically ill COVID-19 ARDS patients showing no significant difference with allogeneic cord blood T-regulatory cells (Tregs). Patients were randomized to receive placebo, 100 million Tregs, or 300 million Tregs with three infusion..